First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Hoosier Cancer Research Network
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Matthew Galsky, Hoosier Cancer Research Network
ClinicalTrials.gov Identifier:
NCT01215136
First received: October 4, 2010
Last updated: August 22, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)